News|Articles|December 10, 2014
Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers
Key Takeaways
- Immunotherapy advancements in hematological cancers, especially Hodgkin lymphoma, show promising potential for treatment improvements.
- The American Society of Hematology's annual meeting highlighted significant progress in blood cancer research.
Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.
Advertisement
Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies. The latest in blood cancer research, including studies involving immunotherapy for Hodgkin lymphoma, were announced at the annual meeting of the American Society of Hematology.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
A Survivor's 30-Year Wait for Lymphedema Relief Ends with Hackensack's New Supermicrosurgery Robotic Procedure
2
Understanding Wills & Estate Planning: LiveLung Augusta’s October Meeting Empowers Patients and Families
3
Harnessing AI and Patient Data to Transform Pancreatic Cancer Research
4
Gastrointestinal Stromal Tumor: Comprehensive Patient Guide
5
